

Comprehensive extractables and leachables characterization through an integrated single injection Quan/Qual analysis using a benchtop multi-reflecting time-of-flight mass spectrometer

Authors: Rachel Sanig¹, Lee A. Gethings¹, Jayne Kirk¹, Richard Lock¹, Shashank Jain²
Affiliations: ¹Waters Corporation, UK ²Waters Corporation, US

Introduction

When screening for extractables and leachables (E&L) from pharmaceutical packaging and medical devices,¹ it is critical to identify all extractables found at levels above the analytical evaluation threshold for toxicological assessment and to quantify low levels of leachable compounds.²

An extractables screening workflow was reported previously using a benchtop multi-reflecting time-of-flight mass spectrometer (MRT MS) for consistent low- to sub-ppm mass accuracy, allowing for increased extractables identification confidence.³ Once extractables are identified a leachables experiment needs to be undertaken, this can be undertaken on the same platform with a highly sensitive ToF MRM analysis.

Here we report a combined analysis approach on one benchtop MRT MS. A time-of-flight multiple reaction monitoring (ToF MRM) mode for targeted quantitation was acquired simultaneously with a data independent acquisition (DIA) mode for confident extractables screening. This dual acquisition schema supports quantitation of known leachables and concurrent monitoring of potential new extractables through screening and identification of unknowns.



Figure 1. Waters Xevo™ MRT P10 Mass Spectrometer and ACQUITY™ Premier System

Experimental

A standard mix (E&L SST) containing typical extractables was injected. Eluate was analyzed using an advanced mixed mode acquisition incorporating, in parallel, targeted and untargeted acquisitions. (DIA scans (MS^E) with scheduled targeted ToF MRM within a single injection.) In addition, a nasal spray solution was spiked with the E&L SST mix to investigate the results in a complex matrix.

LC CONDITIONS: ACQUITY Premier System

Column	ACQUITY CORTECS™ C18, 90 Å (1.6 µm, 2.1 x 100 mm)
Mobile Phase A / B	Water + 1 mM ammonium acetate + 0.1% formic acid / Methanol
Flow Rate	0.3 mL/min
Column Temp.	50 °C
Injection vol.	1 µL
Gradient	15 minutes

MS CONDITIONS: Xevo MRT P10 MS

Acquisition range	m/z 50-1200
MS ^E Scan Speed	10 Hz
MRM dwell time	Optimized per MRM
Source/Desolvation temp	120 °C / 550 °C
Desolvation/Cone gas flow	800 / 50 L/hr
Column Temp.	ESI+ 2.5 kV ESI- 1.5 kV
Collision energy	Low: 6 eV High: 20-60 eV

Data Management

The waters_connect™ Software Platform was used for data acquisition and the UNIFI™ Application and MS Quan application out of the waters_connect Software Platform were used for data processing.

Results

ToF MRM utilizes an Enhanced Duty Cycle (EDC) mode, where target ions are trapped and released with timing synchronization with the pusher. Ion utilization over a specific m/z range approaches 100%, increasing the sensitivity of the assay.⁴

MS^E is a data independent approach where alternating low collision and high collision energy is applied, enabling the acquisition of both precursor and fragment ions throughout the entire chromatographic run.⁵

Combining these two modes in one injection allows for highly sensitive quantitation whilst enabling retrospective extractables screening. Figure 2 shows the sensitivity gains with the MRM transitions compared to the XIC of Ethanox™ 1330 from MS^E mode acquired in the same injection.




Figure 2. Overlaid chromatograms of MS^E and two MRM transitions acquired in the same injection for Ethanox™ 1330.




Figure 4. Standard addition calibration curve for Irganox 1076.

Using the software, a standard addition approach was utilized for any compounds that are present in the blanks. For example, for Irganox™ 1076, the spiked concentration in the samples was calculated to be 10.7 ng/mL (actual concentration 10 ng/mL). (Figure 4)

Conclusions

- **Advanced mixed mode acquisition of quan/qual data in one injection to address a real workflow bottleneck in E&L analysis.**
- **Targeted leachables quantitative analysis with a highly sensitive ToF MRM mode.**
- **Concurrent MS^E mode acquisition for retrospective data interrogation with high mass accuracy precursor and fragment ion data for confident identifications.**

Optimized ToF MRM transitions were acquired to quantify E&L compounds at trace levels. The propylparaben calibration curve, in negative ionization mode, was linear from 0.01 ng/mL (S/N 23) to 100 ng/mL (R² 0.99). An average of the concentrations of the replicate spiked compound in the sample was calculated to be 10.04 ng/mL (actual concentration 10 ng/mL). (Figure 3)




Figure 3. Propylparaben calibration curve. Table 1. Calculated concentration of propylparaben in the spiked sample.

The MS^E data, acquired during the same experiment, were screened against the Waters E&L library for identification. The spiked standards were confidently identified in addition to other library matches, including erucamide (Figure 5). Data generated in this study provided mass accuracies with an RMS of low- to sub-ppm. This significantly narrows the window of possible compounds and vastly increases the confidence in the identifications returned.




Figure 5. Putative identification of protonated m/z 338.3417 (mass error 0.94 ppm) as erucamide from MS^E. Mass fragment 321.3152 m/z (mass error 0.34 ppm).

References

1. USP-NF/PF, <1664> Assessment of Drug Product Leachables Associated with Pharmaceutical Packaging/Delivery Systems. https://doi.usp.org/USPNF/USPNF_M7127_03_01.html
 2. ISO 10993-18:2020 Biological evaluation of medical devices — Part 18: Chemical characterization of medical device materials within a risk management process. <https://www.iso.org/standard/64750.html>
 3. Sanig R., Kirk J., Gethings L., Lock R. Increased Identification Confidence for Extractables Screening Using the Xevo™ MRT Mass Spectrometer. Waters Application Note 720008970. August 2025.
 4. Daly M., Gethings L., Hughes C., Lock R., Syed N. ToF MRM for the Quantification of Peptide Biomarkers in Human Glioblastoma with the Xevo™ MRT Mass Spectrometer. Waters Application Note 720008972, October 2025.
 5. Stevens D., Cabovska B., Bailey A. Detection and Identification of Extractable Compounds from Polymers. Waters Application Note 720004211. January 2012.
- Xevo, ACQUITY, CORTECS, UNIFI, and waters_connect are trademarks of Waters Corporation or its Affiliates. The authors declare no competing financial interest. Ethanox is a trademark of SI Group, Inc. Irganox is a trademark of BASF Group. 720009426EN